5 Key Takeaways

• 1

  Regeneron Genetics Center studies deidentified genomic and health data from more than 3 million people to identify genes and pathways associated with disease and protection.

• 2

  Historically, drug targets supported by human genetics have been 2 to 3 times more likely to succeed and eventually receive approval.

• 3

  Natural genetic variants that activate or inactivate pathways can help researchers anticipate the effects of modifying those pathways with medicines.

• 4

  In a study of more than 1 million DNA samples, rare FNIP1 mutations were associated with favorable metabolic measures and an approximately 60% lower risk of cardiometabolic disease.

• 5

  Lotta said genomic discoveries may help explain individual differences in disease predisposition, while personalized medicine remains at an early stage.